Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.86M Sell
15,732
-3,440
-18% -$397K 0.02% 793
2026
Q1
$2.29M Buy
19,172
+305
+2% +$40K 0.03% 652
2025
Q4
$2.57M Sell
18,867
-530
-3% -$76.2K 0.03% 617
2025
Q3
$2.86M Buy
19,397
+1,523
+9% +$211K 0.03% 584
2025
Q2
$2.31M Sell
17,874
-5,170
-22% -$626K 0.03% 669
2025
Q1
$2.75M Sell
23,044
-12,570
-35% -$1.56M 0.04% 575
2024
Q4
$4.13M Sell
35,614
-1,169
-3% -$148K 0.05% 415
2024
Q3
$4.97M Buy
36,783
+1,216
+3% +$163K 0.06% 351
2024
Q2
$4.82M Sell
35,567
-1,182
-3% -$161K 0.06% 345
2024
Q1
$4.75M Sell
36,749
-4,308
-10% -$521K 0.07% 349
2023
Q4
$4.7M Buy
41,057
+6,204
+18% +$619K 0.07% 313
2023
Q3
$3.17M Buy
34,853
+3,062
+10% +$316K 0.06% 413
2023
Q2
$3.58M Buy
31,791
+1,343
+4% +$142K 0.06% 362
2023
Q1
$3.19M Buy
30,448
+877
+3% +$91.6K 0.06% 378
2022
Q4
$3.27M Sell
29,571
-871
-3% -$91.3K 0.07% 361
2022
Q3
$2.66M Buy
30,442
+4,374
+17% +$398K 0.06% 396
2022
Q2
$2.04M Buy
26,068
+3,126
+14% +$258K 0.04% 503
2022
Q1
$1.96M Buy
22,942
+2,607
+13% +$250K 0.03% 580
2021
Q4
$2.44M Buy
20,335
+963
+5% +$120K 0.04% 485
2021
Q3
$2.4M Buy
19,372
+2,256
+13% +$290K 0.04% 448
2021
Q2
$2.05M Buy
17,116
+3,711
+28% +$424K 0.04% 493
2021
Q1
$1.41M Sell
13,405
-591
-4% -$59.9K 0.03% 580
2020
Q4
$1.43M Buy
13,996
+613
+5% +$57.6K 0.03% 540
2020
Q3
$1.13M Sell
13,383
-6,625
-33% -$516K 0.03% 524
2020
Q2
$1.3M Buy
20,008
+990
+5% +$65.3K 0.04% 427
2020
Q1
$1.24M Buy
19,018
+9,179
+93% +$723K 0.1% 201
2019
Q4
$775K Buy
9,839
+1,991
+25% +$155K 0.02% 623
2019
Q3
$625K Buy
7,848
+1,681
+27% +$132K 0.02% 534
2019
Q2
$466K Buy
6,167
+3,072
+99% +$245K 0.02% 607
2019
Q1
$245K Sell
3,095
-1,660
-35% -$121K 0.01% 789
2018
Q4
$317K Sell
4,755
-189
-4% -$13.1K 0.01% 637
2018
Q3
$395K Sell
4,944
-3,524
-42% -$263K 0.02% 672
2018
Q2
$571K Buy
+8,468
New +$615K 0.03% 526

Other funds holding XYL

Atria Investments's XYL Position: Q2 2026 in Review

Atria Investments reduced its Xylem (XYL) stake by 18% in Q2 2026, selling an estimated $397K and leaving 15,732 shares worth $1.86M. The position accounts for 0.02% of the portfolio, ranked #793.

Atria Investments first reported a position in XYL in Q2 2018 and has held it in 33 quarters since. The position peaked at $4.97M in Q3 2024. 1,093 funds tracked by Wall St. Rank hold XYL as of Q2 2026.

  • Atria Investments held 15,732 shares of Xylem worth $1.86M as of Q2 2026.
  • Atria Investments sold 3,440 Xylem shares in Q2 2026, an estimated $397K.
  • Xylem made up 0.02% of Atria Investments's portfolio in Q2 2026, its #793 holding.
  • Atria Investments first reported a position in Xylem in Q2 2018 and has held it in 33 quarters since.
  • Atria Investments's Xylem position peaked at $4.97M in Q3 2024.
  • 1,093 funds tracked by Wall St. Rank held Xylem as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.